Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-28 23:47:11 - browse：175

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Fertility clinic egg and embryo storage is a disaster

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Departing Stanford president retracts two papers

ALS treatment from Biogen, Ionis fails in study

Appeals court upholds limits to abortion pill

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Obesity drug from Roche shows promise in early study

focus

Wikipedia

leisure time

Drug repurposing or repositioning? The language matters

2024 GOP presidential candidates spar over abortion in debate

Alkermes shareholders re

Hottest summer in 2,000 years puts focus on extreme heat, health

Novavax promises a turnaround & Lilly roils the obesity market

Departing Stanford president retracts two papers

How to save PrEP access — and even expand it

Neuroscience startup Neumora files for IPO

Malaria cases in Florida and Texas: Here’s what you need to know

CDC advisory panel says seniors 'may' get RSV vaccine

Wikipedia

Australia’s approach to dialysis celebrates life

Departing Stanford president retracts two papers

Oak Street deal isn't the answer to health care's woes

What do new weight loss drugs mean for bariatric surgery?

Fertility clinic egg and embryo storage is a disaster

Why more medical students aren't specializing in primary care

focus

hotspot

leisure time

focus